Assessment of cytokine-modulated proteasome activity

Methods in Molecular Biology

Volumn 1172, Issue , 2014, Pages 147-162

  Kirk, Christopher J ^a   Powell, Saul R ^a   Miller, Edmund J ^a  

^a NONE

Author keywords

ATP dependent Activity; Chymotryptic activity; Immunoproteasome; ProCISE; Proteasome

Indexed keywords

CYTOKINE; PROTEASOME; ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ANTIBODY; CYSTEINE PROTEINASE INHIBITOR; FLUORESCENT DYE; HORSERADISH PEROXIDASE; LACTACYSTIN; PEPTIDE; PROTEIN SUBUNIT; TISSUE EXTRACT;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; INFLAMMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; CHEMISTRY; HUMAN; IMMUNOASSAY; KINETICS; LUMINESCENCE; METABOLISM; PROTEIN DEGRADATION; PROTEIN SUBUNIT; SPECTROFLUOROMETRY; SYNTHESIS;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBODIES; CATALYTIC DOMAIN; CYSTEINE PROTEINASE INHIBITORS; CYTOKINES; FLUORESCENT DYES; HORSERADISH PEROXIDASE; HUMANS; IMMUNOASSAY; KINETICS; LUMINESCENT MEASUREMENTS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; PROTEOLYSIS; SPECTROMETRY, FLUORESCENCE; TISSUE EXTRACTS;

EID: 84922480785     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0928-5_13     Document Type: Article

References (59)

1. Dean RT (1979) Lysosomes and protein degradation. Ciba Found Symp 75:139–149
2. Murachi T, Tanaka K, Hatanaka M et al (1980) Intracellular Ca2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzyme Regul 19: 407–24
3. Arrigo AP, Tanaka K, Goldberg AL et al (1988) Identity of the 19S ‘prosome’ particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 331:192–4
4. Wolf DH, Hilt W (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta 1695: 19–31
5. Angeles A, Fung G, Luo H (2012) Immune and non-immune functions of the immunoproteasome. Front Biosci 17:1904–16
6. Ebstein F, Kloetzel PM, Kruger E et al (2012) Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci 69:2543–58
7. Wang X, Li J, Zheng H et al (2011) Proteasome functional insuffi ciency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 301: H2207–19
8. Powell SR, Herrmann J, Lerman A et al (2012) The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci 109:295–346
9. Schmidt N, Gonzalez E, Visekruna A et al (2010) Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59:896–906
10. Conner EM, Brand S, Davis JM et al (1997) Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 282:1615–22
11. Takaoka M, Itoh M, Hayashi S et al (1999) Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. Eur J Pharmacol 384:43–6
12. Zaouali MA, Bardag-Gorce F, Carbonell T et al (2013) Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Pathol 94:352–9
13. Zu L, Bedja D, Fox-Talbot K et al (2010) Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. J Mol Cell Cardiol 49:5–15
14. Otoda T, Takamura T, Misu H et al (2013) Proteasome dysfunction mediates obesityinduced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes 62:811–24
15. Weiss CH, Budinger GR, Mutlu GM et al (2010) Proteasomal regulation of pulmonary fi brosis. Proc Am Thorac Soc 7:77–83
16. Opattova A, Filipcik P, Cente M et al (2013) Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome. J Alzheimers Dis 33:339–48
17. Palmowski MJ, Gileadi U, Salio M et al (2006) Role of immunoproteasomes in crosspresentation. J Immunol 177:983–90
18. Wang J, Maldonado MA (2006) The ubiquitinproteasome system and its role in infl ammatory and autoimmune diseases. Cell Mol Immunol 3:255–61
19. Christmann RB, Mathes A, Affandi AJ et al (2013) Thymic stromal lymphopoietin is upregulated in the skin of patients with systemic sclerosis and induces profi brotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor beta. Arthritis Rheum 65:1335–46
20. Connor AM, Mahomed N, Gandhi R et al (2012) TNFalpha modulates protein degradation pathways in rheumatoid arthritis synovial fi broblasts. Arthritis Res Ther 14:R62
21. Vereecke L, Beyaert R, van Loo G (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30:383–91
22. Kanazawa N (2012) Rare hereditary autoinfl ammatory disorders: towards an understanding of critical in vivo infl ammatory pathways. J Dermatol Sci 66:183–9
23. Grune T, Jung T, Merker K et al (2004) Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during oxidative stress, aging, and disease. Int J Biochem Cell Biol 36:2519–30
24. Jung T, Grune T (2012) Structure of the proteasome. Prog Mol Biol Transl Sci 109:1–39
25. Qureshi N, Morrison DC, Reis J (2012) Proteasome protease mediated regulation of cytokine induction and infl ammation. Biochim Biophys Acta 1823:2087–93
26. Song X, von Kampen J, Slaughter CA et al (1997) Relative functions of the alpha and beta subunits of the proteasome activator, PA28. J Biol Chem 272:27994–8000
27. Zhang Z, Krutchinsky A, Endicott S et al (1999) Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero- oligomers are heptamers. Biochemistry 38:5651–8
28. Stohwasser R, Salzmann U, Giesebrecht J et al (2000) Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28. Eur J Biochem 267:6221–30
29. Whitby FG, Masters EI, Kramer L et al (2000) Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408:115–20
30. Glynne R, Powis SH, Beck S et al (1991) A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 353:357–60
31. Martinez CK, Monaco JJ (1991) Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene. Nature 353: 664–7
32. Nandi D, Jiang H, Monaco JJ (1996) Identifi cation of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol 156:2361–4
33. Groll M, Ditzel L, Lowe J et al (1997) Structure of 20S proteasome from yeast at 2.4A resolution. Nature 386:463–71
34. Tanahashi N, Murakami Y, Minami Y et al (2000) Hybrid proteasomes. Induction by interferon-gamma and contribution to ATPdependent proteolysis. J Biol Chem 275: 14336–45
35. Murata S, Sasaki K, Kishimoto T et al (2007) Regulation of CD8+ T cell development by thymus-specifi c proteasomes. Science 316: 1349–53
36. Calise J, Powell SR (2013) The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 304:H337–49
37. Drews O, Wildgruber R, Zong C et al (2007) Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol Cell Proteomics 6:2021–31
38. Zhou HJ, Aujay MA, Bennett MK et al (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52:3028–38
39. Screen M, Britton M, Downey SL et al (2010) Nature of pharmacophore infl uences active site specifi city of proteasome inhibitors. J Biol Chem 285:40125–34
40. Kirk CJ (2012) Discovery and development of second-generation proteasome inhibitors. Semin Hematol 49:207–14
41. Rajkumar SV, Richardson PG, Hideshima T et al (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630–9
42. Chen D, Frezza M, Schmitt S et al (2011) Bortezomib as the fi rst proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11: 239–253
43. Pahl HL, Baeuerle PA (1996) Control of gene expression by proteolysis. Curr Opin Cell Biol 8:340–7
44. Gotze S, Bose A, Abele D et al (2013) Pitfalls in invertebrate proteasome assays. J Exp Biol 216: 1351–1354
45. Reinheckel T, Sitte N, Ullrich O et al (1998) Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335 (Pt 3):637–42
46. Powell SR, Davies KJ, Divald A (2007) Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. J Mol Cell Cardiol 42:265–9
47. Muchamuel T, Basler M, Aujay MA et al (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15:781–7
48. Bennett MK, Buchholz TJ, Demo SD et al (2006) Compounds for enzyme inhibition. US Patent No: 2006/0088471 A1, USA
49. Moravec RA, O'Brien MA, Daily WJ et al (2009) Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem 387:294–302
50. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739–58
51. Kisselev AF, Goldberg AL (2005) Monitoring activity and inhibition of 26S proteasomes with fl uorogenic peptide substrates. Methods Enzymol 398:364–78
52. French SW, Mayer RJ, Bardag-Gorce F et al (2001) The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs. Alcohol Clin Exp Res 25:225S–229S
53. Divald A, Kivity S, Wang P et al (2010) Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 106: 1829–38
54. Powell SR, Samuel SM, Wang P et al (2008) Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. J Mol Cell Cardiol 44:618–21
55. Wang X, Robbins J (2006) Heart failure and protein quality control. Circ Res 99: 1315–28
56. Ferrington DA, Gregerson DS (2012) Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci 109: 75–112
57. Lightcap ES, McCormack TA, Pien CS et al (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673–83
58. Parlati F, Lee SJ, Aujay M et al (2009) Carfi lzomib can induce tumor cell death through selective inhibition of the chymotrypsinlike activity of the proteasome. Blood 114: 3439–47
59. Rodgers KJ, Dean RT (2003) Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 35:716–27